Cargando…
Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation
Autores principales: | Adnan Awad, Shady, Brück, Oscar, Shanmuganathan, Naranie, Jarvinen, Timo, Lähteenmäki, Hanna, Klievink, Jay, Ibrahim, Hazem, Kytölä, Soili, Koskenvesa, Perttu, Hughes, Timothy P., Branford, Susan, Kankainen, Matti, Mustjoki, Satu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021312/ https://www.ncbi.nlm.nih.gov/pubmed/35443743 http://dx.doi.org/10.1038/s41408-022-00667-9 |
Ejemplares similares
-
NGS in CML - New standard diagnostic procedure?
por: Branford, Susan, et al.
Publicado: (2019) -
RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses
por: Adnan Awad, Shady, et al.
Publicado: (2020) -
Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia
por: Hohtari, Helena, et al.
Publicado: (2022) -
Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets
por: Adnan-Awad, Shady, et al.
Publicado: (2020) -
Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia
por: Hohtari, Helena, et al.
Publicado: (2022)